Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Friday, AnalystRatings.Net reports. They currently have a $126.00 price objective on the stock. Zacks‘ price target indicates a potential upside of 5.03% from the stock’s previous close.
Zacks‘ analyst wrote, “Alexion’s third quarter 2013 adjusted earnings of $0.72 per share surpassed the Zacks Consensus Estimate by a penny and the year-ago earnings by 36%. Results were driven by increased revenues thanks to the continued strong performance by Soliris. Soliris sales soared driven by new patient additions in the PNH indication. The successful label expansion of Soliris into the aHUS indication boosted revenues further. Alexion upped its revenue as well as earnings guidance for 2013. Growth at Alexion is expected to be driven by strong Soliris sales. We believe that the current price reflects all the positive news and hence revert to a Neutral recommendation on the stock.”
ALXN has been the subject of a number of other recent research reports. Analysts at Oppenheimer raised their price target on shares of Alexion Pharmaceuticals from $115.00 to $125.00 in a research note to investors on Friday, October 25th. Separately, analysts at Jefferies Group raised their price target on shares of Alexion Pharmaceuticals from $97.00 to $106.00 in a research note to investors on Friday, October 25th. They now have a “hold” rating on the stock. Finally, analysts at Guggenheim raised their price target on shares of Alexion Pharmaceuticals from $127.00 to $130.00 in a research note to investors on Friday, October 25th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $121.33.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 2.51% on Friday, hitting $122.985. 1,078,857 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52-week low of $81.82 and a 52-week high of $126.39. The stock has a 50-day moving average of $115.2 and a 200-day moving average of $106.8. The company has a market cap of $24.114 billion and a price-to-earnings ratio of 67.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter last year, the company posted $0.60 earnings per share. Alexion Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. On average, analysts predict that Alexion Pharmaceuticals will post $3.04 earnings per share for the current fiscal year.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.